BioNTech SE (BNTX)

The market roared, but the pros did not tag along in size. They either have to catch up, or they are just not coming.

Expanded economic hardship if not outright contraction in two to three years is exactly what Treasury markets are signaling.

The Nasdaq Composite suffered a 'death cross' back in mid-February and what happened after that is now clear to see.

Investment experts pick their favorites in the sector for 2022, ranging from diagnostics to medical devices and medical marijuana to drug development.

In short, Friday was simply an absolute disaster for the U.S. in macroeconomic terms.

Bear in mind that as Omicron threatens to, and will to some degree, slow economic activity, the real catalyst will be the political and policy response.

The fact is that some blood hit the floor on Monday.

Yes, volatility beckons. I hear it too. There may be a revaluation of equities across the board in 2022.

Plus, a quick look at earnings report winners and losers from Thursday after the market closed.

I remain more comfortable trading than investing until there is at least one notably upward trading day on notably higher aggregate trading volume.

Plus, One must ask themselves... Are Russia and China satisfied with making Ukraine and Taiwan uncomfortable? Do they understand the costs?

Stick with energy stocks, and realize that in the current no-yield world stocks are bonds.

Whether panicked sales over these past few days, especially Wednesday, prove to be either the 'fast' or 'smart' money remains to be seen.

Sector selection will remain paramount as pandemic effects continue to permeate.

Satya Nadella's decision to sell almost half his stake in Mr. Softee prompts a closer technical look at what may lie ahead for the tech giant's shares.

I wouldn't expect a lot in the way of economic shutdowns, at least not unless clear evidence presents that people are getting sicker from Omicron.

PFE has created what appears to potentially be the most effective antiviral for those already infected.

Small-cap biotech names are seeing dramatic, widespread declines, creating a liquidation sale for investors.

It was almost nice to be reminded that the saloon doors to the financial markets still swing both ways.

Did anyone else see the semi-annual Financial Stability Report?

Pfizer attributed the quarter's sales of Comirnaty, the firm's Covid-19 Messenger RNA vaccine, for the size of the top and bottom line beats.

While cryptocurrencies are indeed an asset class, and they are divisible, they do not serve as a medium of exchange, and remain unproven as a store of value.

I attended the LD Micro Conference in Los Angeles. Here's what I found out.

With earnings season starting in earnest Wednesday, both indexes have offered investors nothing but lower highs coupled with lower lows since the start of September.

Plus, a look at where central bank policies appear to be heading.

It was as if markets heard what they wanted to hear, when it was actually much more simple: markets heard exactly what they had anticipated.

The New York Fed's August Survey of Consumer Expectations could be problematic.